About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Nxera Pharma Co., Ltd.(4565) Summary

4565
TSE Prime
Nxera Pharma Co., Ltd.
747
JPY
+60
(+8.73%)
Apr 10, 11:17 am JST
5.08
USD
Apr 9, 10:17 pm EDT
Result
PTS
outside of trading hours
746.7
Apr 10, 11:16 am JST
Summary Chart Historical News Financial Result
PER
PBR
0.98
Yield
ー%
Margin Trading Ratio
456.65
Stock Price
Apr 10, 2025
Opening Apr 10, 9:12 am
752 JPY 5.10 USD
Previous Close Apr 9
687 JPY 4.72 USD
High Apr 10, 9:20 am
759 JPY 5.15 USD
Low Apr 10, 9:15 am
732 JPY 4.96 USD
Volume
757,300
Trading Value
0.57B JPY 3.86M USD
VWAP
747.49 JPY 5.09 USD
Minimum Trading Value
74,700 JPY 508 USD
Market Cap
0.07T JPY 0.46B USD
Number of Trades
868
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
1,542
1-Year High Aug 29, 2024
10,428
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 151,900 5,537,900 36.46
Mar 28, 2025 330,500 6,111,600 18.49
Mar 21, 2025 242,100 5,939,600 24.53
Mar 14, 2025 162,900 6,113,500 37.53
Mar 7, 2025 153,500 6,437,700 41.94
Company Profile
Nxera Pharma Co., Ltd. is a drug discovery venture specializing in the development of drugs targeting membrane protein GPCRs in areas such as neurology, immunology, and gastroenterology.
Sector
Pharmaceuticals
Nxera Pharma Co., Ltd. is a biopharmaceutical company with a core focus on a drug discovery platform targeting GPCRs (G protein-coupled receptors), handling everything from research and development to sales of pharmaceuticals. The company is actively pursuing a growth strategy through acquisitions. Its UK subsidiary is responsible for drug discovery, translational medicine, preclinical and early clinical development. Clinical development and sales in Japan and Korea are managed by a wholly-owned subsidiary based in Japan and a subsidiary based in Korea, respectively. The company also envisions future business expansion into the APAC (Asia-Pacific) region. Nxera Pharma's strengths lie in GPCR structural analysis using StaR technology, early-stage lead compound generation, and candidate exploration. The company has established a global drug discovery network.